Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Li-Xuan Qin

Showing results (121-130 of 131) with videos related to

Pageof 14
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2025
Circulating tumor DNA as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with advanced gastrointestinal stromal tumorsCiara M Kelly, Martina Bradic, Sara Saunds, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2022
Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal TumorPing Chi, Li-Xuan Qin, Bastien Nguyen, et al.
The Lancet. Oncology|March 13, 2013
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trialGary K Schwartz, William D Tap, Li-Xuan Qin, et al.
Elife|October 15, 2020
Correction: A chemical probe of CARM1 alters epigenetic plasticity against breast cancer cell invasionXiao-Chuan Cai, Tuo Zhang, Eui-Jun Kim, et al.
Cancer Research Communications|December 1, 2025
Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated LiposarcomaEvan Rosenbaum, Rodrigo Gularte-Mérida, Evan Seffar, et al.
Nature Communications|June 17, 2022
Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcomaSandra P D'Angelo, Allison L Richards, Anthony P Conley, et al.
Elife|October 29, 2019
A chemical probe of CARM1 alters epigenetic plasticity against breast cancer cell invasionXiao-Chuan Cai, Tuo Zhang, Eui-Jun Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2026
Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcome in SarcomaEvan Rosenbaum, Fiona Ehrich, Mohammad Yosofvand, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2023
Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated LiposarcomaCaroline E Gleason, Mark A Dickson, Mary E Klein Dooley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2023
Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA TrialFloris S Verheij, Dana M Omer, Hannah Williams, et al.
Pageof 14

Showing results (121-130 of 131) with videos related to

Sort By:
Pageof 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2025
Circulating tumor DNA as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with advanced gastrointestinal stromal tumorsCiara M Kelly, Martina Bradic, Sara Saunds, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2022
Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal TumorPing Chi, Li-Xuan Qin, Bastien Nguyen, et al.
The Lancet. Oncology|March 13, 2013
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trialGary K Schwartz, William D Tap, Li-Xuan Qin, et al.
Elife|October 15, 2020
Correction: A chemical probe of CARM1 alters epigenetic plasticity against breast cancer cell invasionXiao-Chuan Cai, Tuo Zhang, Eui-Jun Kim, et al.
Cancer Research Communications|December 1, 2025
Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated LiposarcomaEvan Rosenbaum, Rodrigo Gularte-Mérida, Evan Seffar, et al.
Nature Communications|June 17, 2022
Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcomaSandra P D'Angelo, Allison L Richards, Anthony P Conley, et al.
Elife|October 29, 2019
A chemical probe of CARM1 alters epigenetic plasticity against breast cancer cell invasionXiao-Chuan Cai, Tuo Zhang, Eui-Jun Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2026
Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcome in SarcomaEvan Rosenbaum, Fiona Ehrich, Mohammad Yosofvand, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2023
Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated LiposarcomaCaroline E Gleason, Mark A Dickson, Mary E Klein Dooley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2023
Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA TrialFloris S Verheij, Dana M Omer, Hannah Williams, et al.
Pageof 14